Search

Descartes-30

Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. … [L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.

Oxidronic acid

Tirabrutinib

Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).

MLN3897

MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

SX-682

Alfa (M7824 or Tgf-beta "Trap"/pd-l1) With CV301 TRICOM in Advanced Solid Tumors (STAT)). … SX-682 is under investigation in clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp

Allocetra

Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune … With infusion, the body's macrophages and dendritic cells can feed on these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals

Biricodar

The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

IN01

Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.

Binodenoson

This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A_2A receptor.

Furazolidone

(From Martindale, The Extra Pharmacopoeia, 30th ed, p514) … A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase.